July 14, 2014—The Health Resources and Services Administration is publishing a new 340B program rule in the Federal Register requiring drug manufacturers to give rural and free-standing cancer hospitals discounts on orphan drugs when used for non-orphan indications, Office of Pharmacy Affairs Director Cmdr. Krista Pedley said today.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)